TABLE 3

Oligonucleotides used in this study

OligoSequence (5′-3′)aSite
NPL2-AGCCAATTACTCATAGACTCC
NPL2-BGCGAAGAGTACATGATGTGA
NPL2-CCGCGGATCCTGTATTCCGTAGCGTTATATCGBamHI
NPL2-DCGCGGATCCGAATTACACTGCCTGCATAAGGBamHI
NPL2-GACTCATAGACTCCCAAACACACACAAATACCAACTCATATATACAGGCCTCCTCTAGTACACTC
NPL2-HTTTTTTCTTTTTTCATTTATATCCCATGCCATGATGTTAACCGGTGCGCGCCTCGTTCAGAATG
NPL2-LCGCGGATCCATGTCTGACGAAGAACATACCBamHI
NPL2-MCCCAAGCTTAGCCGGTAGATATGCGCHindIII
TIF51A-1CGCGGATCCATGTCTGACGAAGAACATACCCCGCTCGAGBamHI TIF51A-2
CCGGTAGATATGCGCXhoI/AvaI
137-ECGCGGATCCCGGACATAAATTAGACTCTAAGGBamHI
137-FCGCGGATCCGTATCTACTCCAAACTTCTATGGBamHI
PAB1-CCGCGGATCCAAGAGGTCATACTGTATGAAGCCBamHI
PAB1-DCGCGGATCCAGTATTTTCCTGGAACCTGTTGGBamHI
WSC1-ACGCGGATCCACTACTTTCGTAGAATTCCTTCCBamHI
WSC1-BCGCGGATCCCTATGTAACTAAGTTAAGGTTGGBamHI
WSC2-ACGCGGATCCATCTAGCACTTCTCCCAGAAGTGCBamHI
WSC2-BCGCGGATCCTGATGGTGATTTGAGACAGACCBamHI
WSC3-ACGCGGATCCAGCCGATTCGTTAGTAGGAATGCBamHI
WSC3-BCGCGGATCCGTACCACAAACATCATTAGAAGCTGCBamHI
  • a Introduced restriction sites are underlined and italics indicate TIF51A sequences.